Intrinsa Needs More Safety Studies In Face Of Potential Off-Label Use

Further safety studies of Procter & Gamble's testosterone patch Intrinsa are necessary prior to approval because of the potential for broad off-label use of the female sexual dysfunction therapy, FDA's Reproductive Health Drugs Advisory Committee said Dec. 2